Who makes CNTO 2476 3.0 x 10^5 cells?

CNTO 2476 3.0 x 10^5 cells is developed by Janssen Research & Development, LLC.

What development phase is CNTO 2476 3.0 x 10^5 cells in?

CNTO 2476 3.0 x 10^5 cells is in Phase 2.

Last reviewed 2026-05-14 · How we verify

CNTO 2476 3.0 x 10^5 cells

Janssen Research & Development, LLC · Phase 2 active Small molecule

At a glance

Generic name	CNTO 2476 3.0 x 10^5 cells
Sponsor	Janssen Research & Development, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CNTO 2476 3.0 x 10^5 cells CI brief — competitive landscape report
CNTO 2476 3.0 x 10^5 cells updates RSS · CI watch RSS
Janssen Research & Development, LLC portfolio CI